MYGN – Myriad Genetics, Inc.

MYGN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

9.49

Margin Of Safety %

Put/Call OI Ratio

0.21

EPS Next Q Diff

0.02

EPS Last/This Y

-0.79

EPS This/Next Y

0.09

Price

5.68

Target Price

5.81

Analyst Recom

3.11

Performance Q

87.46

Upside

-411.3%

Beta

1.61

Ticker: MYGN

23 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-13	MYGN	4.07	0.11	0.00	4823
2026-10-14	MYGN	4.14	0.11	0.00	4823
2026-10-15	MYGN	4.34	0.11	0.00	4823
2026-10-16	MYGN	3.97	0.11	0.00	5023
2026-10-19	MYGN	4.22	0.10	0.00	4699
2026-10-20	MYGN	5.55	0.10	0.16	4700
2026-10-21	MYGN	5.55	0.17	0.23	6314
2026-10-22	MYGN	5.72	0.17	0.19	6283
2026-10-23	MYGN	5.84	0.17	0.21	6292
2026-10-26	MYGN	6.03	0.17	0.13	6312
2026-10-27	MYGN	6.28	0.17	0.50	6301
2026-10-28	MYGN	6.64	0.17	0.03	6219
2026-10-29	MYGN	6.66	0.17	0.10	6206
2026-10-30	MYGN	6.33	0.17	1.59	6192
2026-11-02	MYGN	5.82	0.17	0.01	6191
2026-11-03	MYGN	6.03	0.20	0.30	5526
2026-11-04	MYGN	6	0.20	1.37	5545
2026-11-05	MYGN	6.29	0.20	0.50	5606
2026-11-06	MYGN	5.91	0.20	3.89	5574
2026-11-09	MYGN	5.74	0.21	0.04	5632
2026-11-10	MYGN	5.66	0.21	0.06	5645
2026-11-11	MYGN	5.7	0.21	0.08	5660
2026-11-12	MYGN	5.68	0.21	0.09	5660
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

23 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-13	MYGN	4.07	0.0	-	-0.74
2026-10-14	MYGN	4.14	0.0	-	-0.74
2026-10-15	MYGN	4.34	0.0	-	-0.74
2026-10-16	MYGN	3.97	0.0	-	-0.74
2026-10-19	MYGN	4.22	0.0	-	-0.74
2026-10-20	MYGN	4.22	0.0	-	-0.74
2026-10-21	MYGN	5.56	0.0	-	-0.74
2026-10-22	MYGN	5.76	0.0	-	-0.74
2026-10-23	MYGN	5.82	0.0	-	-0.74
2026-10-26	MYGN	6.02	0.0	-	-0.74
2026-10-27	MYGN	6.28	0.0	-	-0.74
2026-10-28	MYGN	6.65	0.0	-	-0.74
2026-10-29	MYGN	6.66	0.0	-	-0.74
2026-10-30	MYGN	6.34	0.0	-	-0.74
2026-11-02	MYGN	5.82	0.0	-	-0.74
2026-11-03	MYGN	6.03	0.0	-	-0.74
2026-11-04	MYGN	6.02	0.0	-	-0.74
2026-11-05	MYGN	6.29	0.0	-	-0.74
2026-11-06	MYGN	5.91	0.0	-	-0.74
2026-11-09	MYGN	5.75	-100.0	-	-0.74
2026-11-10	MYGN	5.65	-100.0	-	-0.69
2026-11-11	MYGN	5.70	-100.0	-	-0.69
2026-11-12	MYGN	5.68	-100.0	-	-0.73
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-13	MYGN	-0.11	-5.02	9.65
2026-10-14	MYGN	-0.11	-5.02	9.65
2026-10-15	MYGN	-0.11	-5.02	9.65
2026-10-16	MYGN	-0.11	-5.02	9.65
2026-10-19	MYGN	-0.11	-4.87	9.65
2026-10-20	MYGN	-0.11	-4.87	9.65
2026-10-21	MYGN	-0.11	-4.87	9.65
2026-10-22	MYGN	-0.11	-4.87	9.65
2026-10-23	MYGN	-0.11	-4.87	9.65
2026-10-26	MYGN	-0.11	-4.45	9.65
2026-10-27	MYGN	-0.11	-4.45	10.46
2026-10-28	MYGN	-0.11	-4.45	10.46
2026-10-29	MYGN	-0.11	-4.45	10.46
2026-10-30	MYGN	-0.11	-4.45	10.46
2026-11-02	MYGN	-0.11	-4.79	10.46
2026-11-03	MYGN	-0.11	-4.79	10.46
2026-11-05	MYGN	-0.11	-4.79	10.46
2026-11-06	MYGN	-0.11	-4.79	10.46
2026-11-09	MYGN	-0.11	-4.92	10.46
2026-11-10	MYGN	-0.11	-4.92	10.46
2026-11-11	MYGN	-0.11	-4.92	9.49
2026-11-12	MYGN	-0.11	-4.92	9.49
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.21

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

-0.11

Institutional Transactions

-4.92

Beta

1.61

Average Sales Estimate Current Quarter

196

Average Sales Estimate Next Quarter

203

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

82.1

Max Drawdown 5-Year %

-90.9

Target Price

5.81

P/E

Forward P/E

PEG

P/S

0.68

P/B

2.02

P/Free Cash Flow

EPS

-1.36

Average EPS Est. Cur. Y

-0.73

EPS Next Y. (Est.)

-0.65

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-16.07

Relative Volume

0.61

Return on Equity vs Sector %

-74.4

Return on Equity vs Industry %

-59.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

◆ MYGN Healthcare

$5.68

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

2/20

Pullback

13/25

Volume

9/15

Valuation

5/20

TP/AR

1/10

Options

8/10

RSI

54.4

Range 1M

60.6%

Sup Dist

1.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

2/25

Growth

3/30

Estimates

3/20

Inst/Vol

3/15

Options

8/10

EPS Yr

-1262.8%

EPS NY

1.1%

52W%

54.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +2.3% upside

Quality

6/30

Valuation

4/30

Growth

5/25

Stability

5/10

LT Trend

1/5

Upside

+2.3%

Quality

MYGN — P/E HistoricalDiagnostics & Research

Myriad Genetics, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 2700

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus's gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

MYGN

Latest News

—

Caricamento notizie per MYGN…

stock quote shares MYGN – Myriad Genetics, Inc. Stock Price stock today

news today MYGN – Myriad Genetics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MYGN – Myriad Genetics, Inc. yahoo finance google finance

stock history MYGN – Myriad Genetics, Inc. invest stock market

stock prices MYGN premarket after hours

ticker MYGN fair value insiders trading

MYGN – Myriad Genetics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: MYGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y